LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

  LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare

Morgan Stanley Global Healthcare Conference 2013

Business Wire

BURLINGTON, N.C. -- September 3, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today
announced that David P. King, Chairman and Chief Executive Officer, is
scheduled to speak at the Morgan Stanley Global Healthcare Conference in New
York, NY. LabCorp’s presentation is planned for Tuesday, September 10, 2013 at
8:00 A.M. (EST).

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon
Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark
Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials
testing through its LabCorp Clinical Trials division. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about our
organization, visit our Web site at:

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.


Investor/Media Contact:
Stephen Anderson, 336-436-5076
Company Information:
Press spacebar to pause and continue. Press esc to stop.